Humacyte 在 V012 三期研究女性透析通路患者中期分析中,Atev 相比标准护理 AV 瘘达到主要优效性终点

美股速递
Jun 11

在针对女性透析通路患者进行的 V012 三期临床试验中期分析中,Humacyte 的 Atev 达到了相较于标准护理动静脉(AV)瘘的主要优效性终点。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10